Gilead rolls out Stribild pill in U.K., Germany; Ireland adopts reference pricing, generics incentives;

@FiercePharma: More Indian hospitals eye anti-Ranbaxy policies, Business Standard reports. Some patients asking to switch. Report | Follow @FiercePharma

@EricPFierce: U.S. arrests 2 Pakistani men for selling controlled substances via the Internet. Interpol tracks them to London. Story | Follow @EricPFierce

@CarlyHFierce: First Ranbaxy, now Wockhardt - what is India to do about its manufacturing problems? Regulators unsure. More | Follow @CarlyHFierce

> Armed with a new approval from European regulators, Gilead Sciences ($GILD) launched its combination HIV pill Stribild in the U.K. and Germany, with Austria, Italy, Spain and the Nordic countries coming soon. Report

> Irish lawmakers passed legislation to introduce reference pricing for drugs and to incentivize use of cheap generics; the measure is expected to take effect next month. Report

> Bayer said U.S. antitrust regulators approved its $1.1 billion acquisition of the contraceptive devices company Conceptus. Report

> Hong Kong's Zuellig Group is selling its Australian pharma wholesaler Symbion to the drug and animal health products company Ebos and will in turn take a 40% stake in the New Zealand company. Report

> India's Cipla posted disappointing results for its fiscal fourth quarter, with sales up 2.4% and net profits down 8%. Report

Medical Device News

@FierceMedDev: Luminex re-ups assay deal with Merck KGaA. News | Follow @FierceMedDev

@DamianFierce: Cyberonics slides after CMS again rejects depression device for reimbursement. Article | Follow @DamianFierce

> Teleflex snags CE mark for balloon catheter. More

> CMS declines coverage for Cyberonics' depression device. Story

> Biosensors bets on 15% annual growth thanks to M&A. Article

> Toshiba, TPG said to bid on Panasonic's billion-dollar health biz. Report

Biotech News

@FierceBiotech: GSK buys Okairos (Fierce 15 profile) for $325M, strengthens vaccines biz. Release | Follow @FierceBiotech

@JohnCFierce: Novo spearheads $175M financing to back Ophthotech's PhIII AMD study. News | Follow @JohnCFierce

@RyanMFierce: UPDATED: GlaxoSmithKline bags genetic vaccine developer Okairos for $325M. Article | Follow @RyanMFierce

@EmilyMFierce: University of Alabama begins Parkinson's biomarker study. Story | Follow @EmilyMFierce

> Alexandria lands anchor R&D tenant for San Francisco biotech cluster. Article

> GenVec seeks liquidation after gene therapy setbacks. Report

> Novo spearheads $175M financing to back Ophthotech's PhIII AMD study. More

> Sights set on Asia, Amgen sets up JV development deal with Astellas. News

Biomarkers News

> New CTC technology looks promising to track evolution of prostate cancer. Report

> Swedish team discovers protein common to aggressive bladder cancer. More

> Cenix to collaborate with Debiopharm on predictive biomarkers. Article

> Pancreatitis or cancer? Mayo Clinic says mutated gene points the way. Story

> Johns Hopkins: Two genes help predict postpartum depression risk. Item

Drug Delivery News

@MichaelGFierce: Morphine delivery platform could diminish abuse potential. Item | Follow @MichaelGFierce

> Shape-shifting nanoparticles anchor to tumor cells, deliver drugs. Story

> New drug targets lock-and-key mechanism of prostate cancer growth. Article

> Covidien completes successful drug-coated balloon trial. More

> Inhalable chemo-carrying nanoparticles target lung cancer directly. Report

And Finally... The fight against malaria in Africa has been hobbled by an influx of phony drugs. Report

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.